This site is intended for use by U.S. residents only.

©2023 CAMCEVI. All rights reserved. WS-CAM-2200004 V7


Discover Camcevi®

syringe icon
The first and only
CAMCEVI is the first AND ONLY sub-Q leuprolide therapy that comes prefilled with no mixing.1
proven icon
Proven leuprolide efficacy*
CAMCEVI was dosed subcutaneously, 42 mg on Day 0 and again at Week 24, and offers consistent suppression of testosterone to castrate levels from Week 4 to Week 48.1
simple icon
Simplified Preparation
CAMCEVI comes prefilled with no mixing required—simplifying syringe prep for you.1
unique icon
Unique J Code
CAMCEVI has unique J Code J1952

*CAMCEVI was evaluated in an open-label, single arm, multinational study involving 137 patients with advanced prostate cancer with a baseline morning serum testosterone level of >150 ng/dL and ECOG performance status of ≤2. CAMCEVI was dosed subcutaneously, 42 mg on Day 0 and again at Week 24.1

The primary endpoint was medical castration rate, defined as achieving and maintaining serum testosterone suppression to ≤50 ng/dL by Week 4 through Week 48 of treatment after the initial injection.1


    Stay informed about
    CAMCEVI with regular updates,
    education, and more.

    *Required fields


    1. CAMCEVI. Prescribing information. Accord BioPharma; May 2021.